So just curious about how you would characterize where you are in the launch of Amulet. Thanks so much.Robert Ford Yeah. Listen, it’s going well. We’ve got a nice kind of ramp. I guess I would say I wanted that ramp to be a little bit more vertical. I would say one of the challenges we face there is exactly like you said, it’s difficult to launch a product right into the pandemic. We saw that with a couple of products also. But I think that the team has done a really good job here of being thoughtful about how to build a strong and sustainable position in the market. We’re not in the entire market.We haven’t gone out and launched into all the accounts, but the accounts that we have launched into, Danielle, we’re actually seeing roughly about a 25% market share into those accounts.
So I think that’s the right kind of base to work off from, ensuring that the accounts that we’re in, we’re starting to see repeat usage, continued usage, expanded usage. And as we start to see more of that then we’ll start to ramp up and start to go to new accounts. So I think this is an exciting area for us.Yeah, I would want it to be a little bit more vertical in terms of its launch, but I’m very optimistic about the product, about the team, about the position that we built in. So and we’re investing in it, right? We’ve got our CATALYST trial here that’s enrolling pretty well too, comparing Amulet to NOACs. So I think this is a great opportunity, a great area of investment and growth for us.Danielle Antalffy Thank you.Scott Leinenweber Operator, we’ll take one more question.Operator Thank you.
And our last question will come from Matt Miksic from Barclays. Your line is open.Matt Miksic Hey, thanks so much for squeezing me in. So covered a lot of ground, obviously, out of here. So maybe, Robert, if I could just ask just one follow-up on your comments this morning, which came across, I think, to most folks as noticeably more bullish and encouraged by what you saw in Q1. And maybe just recognizing that investor expectations have also risen a bit throughout Q1 as checks and everything came in during the quarter, but would you describe what you’re seeing in the environment as something like a volume recovery or some other companies have used this backlog concept or something that might — is strong now and may ease whenever — later in the year?
Or is what you’re seeing maybe something more general in terms of lifting productivity and volumes that could be more sustainable? Thanks.Robert Ford Yeah. I guess the way to — the way I’m seeing this, and I’ve travelled quite a bit during this first quarter and I made the statement in my opening remarks. I sense in talking to systems and talking to consumers, again, not just in the US, but around the world that there is this focus now of, okay, COVID is behind us, but I want to stay healthy, I want to get healthy, and I want to stay there.So as it relates to procedures, what I’m seeing is people say, listen, I’ve been putting this off not because of COVID, not because there’s some sort of backlog, but I’ve been putting this off for a couple of years.
I want to go and address this or on the consumer side of our products, whether it’s EPD or Nutrition, we’re seeing, again, a lot more focus on, okay, I’m going to spend some of my disposable income on these products, on these health products.So I don’t see this as like a backlog aspect here that we’re going to work our way through. Maybe there is some areas or geographies that you might have a little bit of that, but we tend to, on the procedure side, we tend to work with the systems and we play a role in preplanning this procedure. So we have a sense of what the funnel is. And I don’t see like this oversized funnel over here because of a backlog. What I do see is more funnel just because people are wanting to invest in their health.And on the flip side of that is I think the systems have figured out, whether it’s in diagnostics or whether it’s in cardio procedures, they figured out how to have to deal with some of these staffing issues that I don’t think are — will ever be back to normal.
So I think that what you’re seeing are systems obviously addressing some of the shortfalls, but — not just by hiring, but also using technology, working with companies to figure out how to offset some of that delta in labor shortage.So I think this is very sustainable. And I think you’re seeing some of the companies that are reporting, yesterday, I think we saw some companies report talk about growth in procedure trend. So I think it is sustainable. I don’t think it’s a bolus of backlog, so at least that’s how we’re seeing it, at least on our products.Matt Miksic That’s great. Thanks so much.Robert Ford I’ll just wrap up here then. I think like I said in my comments, I think we’re off to — we’re definitely off to a very strong start to the year here.
Growth in our underlying base business has accelerated, and it’s strong, and it’s across the board, whether it’s the different product groups, platforms or geographies.We’re now forecasting at least high single-digit growth in our underlying base business here. And I think this is a pretty unique and differentiated growth profile. Part of it is market conditions improving, but I also think part of it is our new product pipeline that continues to be highly productive.So we’re really pleased with how we started off the year. And with that, we’ll wrap up, and thank you for joining us.Scott Leinenweber Thank you, operator, and thank you for all of your questions. This now concludes Abbott’s conference call. A webcast replay of this call will be available after 11:00 A.M. Central Time today on Abbott’s Investor Relations website at abbottinvestor.com.
Thank you for joining us.Operator Thank you. This concludes today’s conference call. Thank you for your participation. You may now disconnect. Everyone have a wonderful day.
